Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Julphar
Fuji
Healthtrust
McKesson
Merck

Generated: May 22, 2019

DrugPatentWatch Database Preview

OXYCONTIN Drug Profile

« Back to Dashboard

Which patents cover Oxycontin, and what generic alternatives are available?

Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twenty patents protecting this drug and seven Paragraph IV challenges.

This drug has five hundred and fifty-three patent family members in forty-eight countries.

The generic ingredient in OXYCONTIN is oxycodone hydrochloride. There are nineteen drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.

Drug patent expirations by year for OXYCONTIN
Pharmacology for OXYCONTIN
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Synonyms for OXYCONTIN
(-)-14-Hydroxydihydrocodeinone
(-)-Oxycodone
(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0;{1,13}.0;{5,17}.0;{7,18}]octadeca-7(18),8,10-trien-14-one
(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
(5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one
124-90-3
124-90-3 (hydrochloride)
14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one
14-Hydroxydihydrocodeinone
4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4aH-8,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-
6-deoxy-7,8-dihydro-14-hydroxy-3-O-methyl-6-oxomorphine
76-42-6
AC-16043
AC1Q4DTG
AKOS015962233
AN-22961
Apo-oxycodone CR
Avridi
BDBM50370595
BRN 0043446
BRUQQQPBMZOVGD-XFKAJCMBSA-N
C08018
CD35PMG570
CHEBI:7852
CHEMBL656
Codeinone, 7,8-dihydro-14-hydroxy-
Codeinone, dihydro-14-hydroxy-
Codeinone, dihydrohydroxy-
Codeinone,8-dihydro-14-hydroxy-
D05312
DB00497
DEA No. 9143
Dihydro-14-hydroxycodeinone
Dihydrohydroxycodeinone
Dihydrohydroxycondeinone
Dihydrone
Dihydroxycodeinone
Diphydrone
DTXSID5023407
EINECS 200-960-2
Endine (Australia)
Endone
Eubine
Eubine [France]
Eucodal
Eucodalum
Eukodal
Eutagen
GTPL7093
HSDB 3142
Hydroxycodeinon
LS-92148
Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-
Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-
Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-
Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI)
Morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-
Morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-
NSC 19043
NSC-19043
NSC19043
Ossicodone
Ossicodone [DCIT]
Oxanest
Oxicodona
Oxicodona [INN-Spanish]
Oxicon
Oxicone
Oxiconum
Oxikon
Oxycodeinon
Oxycodeinone
Oxycodon
oxycodone
Oxycodone (USAN/INN)
Oxycodone [USAN:INN:BAN]
Oxycodone 0.1 mg/ml in Methanol
Oxycodone 1.0 mg/ml in Methanol
Oxycodone Concentrate
Oxycodone hydrochloride
Oxycodone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Oxycodonum
Oxycodonum [INN-Latin]
Oxycon
Oxycone
Oxyfast
OxyIR
Oxyneo
Pancodine
Pancodone Retard
Pancodone retard (United Kingdom)
Percobarb
Percodan
Percolone
PF-00345439
PF06
PTI-821
Roxicodone
SCHEMBL2737
Supendol
Supendol [Canada]
Supeudol
Tecodin
Tekodin
Tekodin (free base)
Thecodine
Thekodin
Theocodin
UNII-CD35PMG570
WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1
Xtampza
Xtampza ER
ZINC403533

US Patents and Regulatory Information for OXYCONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-004 Apr 5, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-003 Apr 5, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-007 Apr 5, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for OXYCONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 ➤ Sign Up ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-004 Apr 5, 2010 ➤ Sign Up ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-001 Apr 5, 2010 ➤ Sign Up ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 ➤ Sign Up ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 ➤ Sign Up ➤ Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-004 Apr 5, 2010 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for OXYCONTIN
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablet 15 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablet 30 mg, 60 mg and 80 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablet 10 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablet 20 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablet 40 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablets 15 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablets 30 mg and 60 mg ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for OXYCONTIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 92292 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Accenture
Cantor Fitzgerald
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.